Adicet Bio, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ACET | DTC.CN | INMB | BCTX | ATRA | INAB | |
|---|---|---|---|---|---|---|
| Market cap | 29.02M | 25.50M | 41.18M | 27.86M | 84.02M | 9.18M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.8 | — | -3.1 | -8.2 | 5.4 | -1.0 |
| Price/book | 0.3 | 7.3 | 1.8 | 1.7 | -2.1 | 0.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −71.38% | −61.05% | −18.40% | −67.55% | −23.72% | −43.92% |
| Today | −2.21% | −1.47% | +0.76% | +5.98% | +2.07% | −2.02% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ACET news ›Adicet Bio, Inc. Announces That Enrollment in Its Prulacabtagene Leucel (Prula-Cel, Formerly Adi-001) Phase 1 Program in Autoimmune Diseases Has Doubled to over 20 Patients
On January 7, 2026, Adicet Bio, Inc. announced that enrollment in its prulacabtagene leucel Phase 1 program in autoimmune diseases has doubled to over 20 patients as of December 31, 2025. The Company... On January 7, 2026, Adicet Bio, Inc…
Adicet Bio, Inc.(NasdaqCM: ACET) added to Russell 3000E Value Benchmark
Adicet Bio, Inc. added to Russell 3000E Value Benchmark... Biotechnology & Medical Research Adicet Bio, Inc.(NasdaqCM:ACET) added to Russell 3000E Value Benchmark Latest news about Adicet Bio, Inc. Chart Adicet Bio, Inc. Income Statement…
Adicet Bio, Inc. Announces Executive Changes
Adicet Bio, Inc. announced Lloyd Klickstein, M.D., Ph.D. appointed Interim Chief Medical Officer. Following the departure of Dr. Julie Maltzman, Dr. Klickstein, who currently serves on the board of... announced Lloyd Klickstein, M.D., Ph.D…
Recent Research Analysts’ Ratings Updates for Adicet Bio (ACET)
Posted by Defense World Staff on Oct 12th, 2026 Adicet Bio (NASDAQ: ACET) has recently received a number of price target changes and ratings updates: Adicet Bio, Inc is a clinical-stage biotechnology company focused on developing…
Adicet Bio Q3 net loss narrows, raises $74.8 mln
Overview * Adicet Bio Q3 net loss narrows to $26.9 mln from $30.5 mln, with reduced operating expenses * Positive preliminary data from Phase 1 trial of ADI-001 in lupus nephritis and SLE ... Biotechnology & Medical Research Adicet Bio Q3…
Adicet Bio announces reverse stock split
Adicet Bio Inc: Adicet Bio announces reverse stock split Adicet Bio Inc - announces one-for-16 reverse stock split ... Biotechnology & Medical Research Adicet Bio announces reverse stock split Published on 12/26/2025 at 09:18 am EST
Adicet Bio, Inc.: Relative Strength Chart - Stock Nasdaq
Compare Adicet Bio, Inc. with the company of your choice via a Relative Strength chart. Real-time ACET price, Nasdaq stock exchange Relative Strength Chart Adicet Bio, Inc. Biotechnology & Medical Research All financial news and data…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com9
- defenseworld.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 10 articles, not a forecast.